Media ReleasesImugene Limited

View All Imugene Limited News


Imugene Limited announces Cancer vaccine shows early promise in gastric cancer clinical trial

Cancer vaccine shows early promise in gastric cancer clinical trial

  • Strong immune responses measured in the first patients dosed
  • Dose escalation recommended after no safety, toxicity or tolerability issues
  • Clinical data will guide recommended dose for planned Phase 2 study
MELBOURNE Australia 07 February 2018: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company is pleased to announce its HER-Vaxx cancer vaccine (IMU-131) is showing early promise in patients with metastatic gastric cancer and feedback from clinicians running the study has been positive.

For further information please download PDF attached: Download this document